Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CVKD
stocks logo

CVKD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.210
-86.14%
--
--
-1.330
-36.36%
--
--
-1.390
-25.67%
Estimates Revision
The market is revising No Change the revenue expectations for Cadrenal Therapeutics, Inc. (CVKD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -16.19%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-16.19%
In Past 3 Month
Wall Street analysts forecast CVKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVKD is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CVKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVKD is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.100
sliders
Low
45.00
Averages
45.00
High
45.00
Current: 11.100
sliders
Low
45.00
Averages
45.00
High
45.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Cadrenal Therapeutics Inc (CVKD.O) is -2.04, compared to its 5-year average forward P/E of -1.94. For a more detailed relative valuation and DCF analysis to assess Cadrenal Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.94
Current PE
-2.04
Overvalued PE
-1.14
Undervalued PE
-2.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.13
Undervalued EV/EBITDA
-2.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CVKD News & Events

Events Timeline

(ET)
2025-12-01
09:10:00
Cadrenal Appoints PTC CMO Dr. Lee Scott Golden to Board of Directors
select
2025-11-10 (ET)
2025-11-10
09:01:27
Cadrenal Therapeutics announces Q3 earnings per share of $1.31, compared to a loss of $2.18 in the same period last year.
select
2025-09-15 (ET)
2025-09-15
08:14:28
Cadrenal Reveals Purchase of eXIthera Pharmaceuticals' Assets
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-01Newsfilter
Cadrenal Therapeutics Appoints Dr. Lee Scott Golden to Board, Enhancing Anticoagulation Development
  • New Board Member: Cadrenal Therapeutics appoints Dr. Lee Scott Golden as an independent director effective immediately, aiming to leverage his extensive experience in cardiovascular medicine and anticoagulation to drive the company's strategy.
  • Clinical Development Expertise: Dr. Golden, serving as Chief Medical Officer at PTC Therapeutics, oversees global clinical development, which is expected to provide crucial guidance for the advancement of Cadrenal's tecarfarin and broader pipeline.
  • Industry Background: With over 25 years in the pharmaceutical industry, including senior roles at Pfizer, Dr. Golden brings valuable insights for managing strategic clinical development plans at Cadrenal.
  • Market Potential: Cadrenal focuses on developing novel anticoagulants to bridge critical gaps in current therapies, which is anticipated to significantly improve treatment outcomes for patients with complex cardiovascular conditions.
[object Object]
Preview
8.5
11-08NASDAQ.COM
Cadrenal Therapeutics, LLC

  • Valuation of Cadrenal Therapeutics: Cadrenal Therapeutics, Inc. (CVKD) is valued at $30.00/share based on a probability-adjusted DCF model that considers future revenues from tecarfarin, contingent on its clinical success.

  • Acquisition of Factor XIa Inhibitors: On September 15, 2025, Cadrenal announced the acquisition of a portfolio of Factor XIa inhibitors from eXIthera Pharmaceuticals, including frunexian, which is being developed as an acute anticoagulant therapy.

  • Clinical Trial Plans for Tecarfarin: Cadrenal plans to initiate a Phase 2 clinical trial for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis in the first quarter of 2026, addressing a significant unmet need for effective anticoagulant therapies.

  • Financial Overview: As of June 30, 2025, Cadrenal reported no revenues and had approximately $5.6 million in cash, indicating the need for additional capital to fund upcoming clinical trials for tecarfarin and frunexian.

[object Object]
Preview
1.0
09-30Newsfilter
Cadrenal Therapeutics to Attend Lytham Partners Fall 2025 Investor Conference on September 30, 2025

  • Company Participation in Investor Conference: Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference with a webcast presentation on September 30, 2025, at 3:30 p.m. ET, and will host one-on-one meetings with investors.

  • About Cadrenal Therapeutics: The company is focused on developing tecarfarin, a novel oral anticoagulant aimed at addressing the limitations of current anticoagulation therapies, particularly for patients with specific conditions like end-stage kidney disease and atrial fibrillation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cadrenal Therapeutics Inc (CVKD) stock price today?

The current price of CVKD is 11.1 USD — it has increased 25.28 % in the last trading day.

arrow icon

What is Cadrenal Therapeutics Inc (CVKD)'s business?

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to overcome the gaps in anticoagulation therapy. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). It also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.

arrow icon

What is the price predicton of CVKD Stock?

Wall Street analysts forecast CVKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVKD is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cadrenal Therapeutics Inc (CVKD)'s revenue for the last quarter?

Cadrenal Therapeutics Inc revenue for the last quarter amounts to -2.73M USD, increased 11.13 % YoY.

arrow icon

What is Cadrenal Therapeutics Inc (CVKD)'s earnings per share (EPS) for the last quarter?

Cadrenal Therapeutics Inc. EPS for the last quarter amounts to -2357150.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Cadrenal Therapeutics Inc (CVKD)'s fundamentals?

The market is revising No Change the revenue expectations for Cadrenal Therapeutics, Inc. (CVKD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -16.19%.
arrow icon

How many employees does Cadrenal Therapeutics Inc (CVKD). have?

Cadrenal Therapeutics Inc (CVKD) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Cadrenal Therapeutics Inc (CVKD) market cap?

Today CVKD has the market capitalization of 22.75M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free